×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SLS – sellas life sciences group, inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SLS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/20
04:05 pm
sls
SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update
Low
Report
SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update
2/20
08:45 am
sls
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
Low
Report
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
1/28
03:11 pm
sls
SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Medium
Report
SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
1/25
05:06 am
sls
Biotech CEO predicts 'revolutionary' steps toward curing cancer on horizon thanks to AI [FOX News]
High
Report
Biotech CEO predicts 'revolutionary' steps toward curing cancer on horizon thanks to AI [FOX News]
1/23
08:10 am
sls
SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
High
Report
SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
1/8
08:20 am
sls
SELLAS Announces Key Business Objectives for 2025
Medium
Report
SELLAS Announces Key Business Objectives for 2025
1/2
08:00 am
sls
SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET
Medium
Report
SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/20
04:07 pm
sls
Form 8-K SELLAS Life Sciences For: Mar 20
Low
Report
Form 8-K SELLAS Life Sciences For: Mar 20
3/20
04:01 pm
sls
Form 10-K SELLAS Life Sciences For: Dec 31
Low
Report
Form 10-K SELLAS Life Sciences For: Dec 31
1/29
11:26 am
sls
Form 424B5 SELLAS Life Sciences
High
Report
Form 424B5 SELLAS Life Sciences
1/29
09:14 am
sls
Form 8-K SELLAS Life Sciences For: Jan 28
High
Report
Form 8-K SELLAS Life Sciences For: Jan 28
1/23
04:42 pm
sls
Form 8-K SELLAS Life Sciences For: Jan 23
Medium
Report
Form 8-K SELLAS Life Sciences For: Jan 23
1/16
04:11 pm
sls
Form 8-K SELLAS Life Sciences For: Jan 10
Medium
Report
Form 8-K SELLAS Life Sciences For: Jan 10
1/14
05:35 pm
sls
Form 4 SELLAS Life Sciences For: Jan 10 Filed by: Burns John Thomas
Low
Report
Form 4 SELLAS Life Sciences For: Jan 10 Filed by: Burns John Thomas
1/14
05:34 pm
sls
Form 4 SELLAS Life Sciences For: Jan 10 Filed by: Stergiou Angelos M.
Low
Report
Form 4 SELLAS Life Sciences For: Jan 10 Filed by: Stergiou Angelos M.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/2
Form 8-K SELLAS Life Sciences For: Jul 01
37.1%
5/31 Form 8-K SELLAS Life Sciences For: May 31 10.3%
8/14 Form 8-K SELLAS Life Sciences For: Aug 14 7.5%
7/15 Form 8-K SELLAS Life Sciences For: Jul 12 6.8%
8/5 Form DEF 14A SELLAS Life Sciences For: Sep 10 4.5%
4/28 SELLAS Releases Annual Letter to Shareholders 4.1%
11/25 Form 8-K SELLAS Life Sciences For: Nov 25 3.1%
2/26 SELLAS Announces Positive Follow-Up Phase 1/2 Clinical Data for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) 1.9%
1/17 Form SC 13G SELLAS Life Sciences Filed by: CVI Investments, Inc. 1.3%
3/16 Form 4 SELLAS Life Sciences For: Mar 12 Filed by: Burns John Thomas 1.1%
5/31 Form 8-K SELLAS Life Sciences For: May 31 10.3%
8/14 Form 8-K SELLAS Life Sciences For: Aug 14 7.5%
7/15 Form 8-K SELLAS Life Sciences For: Jul 12 6.8%
8/5 Form DEF 14A SELLAS Life Sciences For: Sep 10 4.5%
4/28 SELLAS Releases Annual Letter to Shareholders 4.1%
11/25 Form 8-K SELLAS Life Sciences For: Nov 25 3.1%
2/26 SELLAS Announces Positive Follow-Up Phase 1/2 Clinical Data for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) 1.9%
1/17 Form SC 13G SELLAS Life Sciences Filed by: CVI Investments, Inc. 1.3%
3/16 Form 4 SELLAS Life Sciences For: Mar 12 Filed by: Burns John Thomas 1.1%
TOP News Decliners
6/14
Form EFFECT SELLAS Life Sciences
-55.6%
11/6 SELLAS Announces Reverse Stock Split -27.8%
5/23 Form S-1 SELLAS Life Sciences -27.0%
7/9 Form 8-K SELLAS Life Sciences For: Jul 08 -19.5%
1/13 SELLAS Highlights Clinical Development Progress and Expected 2020 Milestones -19.4%
11/14 Form 8-K SELLAS Life Sciences For: Nov 14 -18.3%
7/31 SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study -18.1%
7/9 Form 8-K SELLAS Life Sciences For: Jul 09 -15.3%
1/8 SELLAS Commences Pivotal Phase 3 REGAL Study of Galinpepimut-S (GPS) in Patients with Acute Myeloid Leukemia (AML) -12.9%
6/6 Form S-1/A SELLAS Life Sciences -10.3%
11/6 SELLAS Announces Reverse Stock Split -27.8%
5/23 Form S-1 SELLAS Life Sciences -27.0%
7/9 Form 8-K SELLAS Life Sciences For: Jul 08 -19.5%
1/13 SELLAS Highlights Clinical Development Progress and Expected 2020 Milestones -19.4%
11/14 Form 8-K SELLAS Life Sciences For: Nov 14 -18.3%
7/31 SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study -18.1%
7/9 Form 8-K SELLAS Life Sciences For: Jul 09 -15.3%
1/8 SELLAS Commences Pivotal Phase 3 REGAL Study of Galinpepimut-S (GPS) in Patients with Acute Myeloid Leukemia (AML) -12.9%
6/6 Form S-1/A SELLAS Life Sciences -10.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: